oral semaglutide for obesity 50 mg of #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://t.co/EFnRupKFV7 Oral drug plus Wegovy preserves

This means that AOD-9604: Does not raise IGF-1 , no systemic anabolic effect Does not cause insulin resistance , a frequent side effect of high doses of hGH Has no growth effect , no influence on the growth of bones, soft tissues, organs Does not cause acromegaly , because it does not act as GH It is one of the few molecules where we have managed to surgically separate one effect of GH (lipolysis) from the others

Cagrilintide + Tirzepatide Clinical Evidence Context Direct stack evidence No published human trial has tested cagrilintide + tirzepatide together

Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort

This one surprises patients

Why does the 'weight-loss plateau' happen